scholarly journals Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of the Urinary Proteome for Measuring the Escitalopram Treatment Response From Major Depressive Disorder

2021 ◽  
Vol 12 ◽  
Author(s):  
Yuhang Huan ◽  
Jing Wei ◽  
Jingjing Zhou ◽  
Min Liu ◽  
Jian Yang ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Urinary Proteins ◽  
Major Depressive ◽  
Efficient Treatment ◽  
Urine Biomarkers ◽  
Differential Proteins ◽  
Treatment Measures ◽  
Response Group ◽  
Pilot Tests

Major depressive disorder (MDD) is a common mental disorder that can cause substantial impairments in quality of life. Clinical treatment is usually built on a trial-and-error method, which lasts ~12 weeks to evaluate whether the treatment is efficient, thereby leading to some inefficient treatment measures. Therefore, we intended to identify early candidate urine biomarkers to predict efficient treatment response in MDD patients. In this study, urine samples were collected twice from 19 respondent and 10 non-respondent MDD patients receiving 0-, 2-, and 12-week treatments with escitalopram. Differential urinary proteins were subsequently analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Our two pilot tests suggested that the urine proteome reflects changes associated with major depressive disorder at the early stage of treatment measures. On week 2, 20 differential proteins were identified in the response group compared with week 0, with 14 of these proteins being associated with the mechanisms of MDD. In the non-response group, 60 differential proteins were identified at week 2, with 28 of these proteins being associated with the mechanisms of MDD. In addition, differential urinary proteins at week 2 between the response and non-response groups can be clearly distinguished by using orthogonal projection on latent structure-discriminant analysis (OPLS-DA). Our small pilot tests indicated that the urine proteome can reflect early effects of escitalopram therapy between the response and non-response groups since at week 2, which may provide potential early candidate urine biomarkers to predict efficient treatment measures in MDD patients.

scholarly journals Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive Disorder—Preliminary Results of the PROVIT Study

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2575
Author(s):  
Alexandra Reiter ◽  
Susanne A. Bengesser ◽  
Anne-Christin Hauschild ◽  
Anna-Maria Birkl-Töglhofer ◽  
Frederike T. Fellendorf ◽  
...  
Keyword(s):  
Gene Expression ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Interleukin 6 ◽  
Intervention Group ◽  
Additional Treatment ◽  
Major Depressive ◽  
Efficient Treatment ◽  
Expression Levels ◽  
Gene Expression Levels

Major depressive disorder (MDD) is a prevalent disease, in which one third of sufferers do not respond to antidepressants. Probiotics have the potential to be well-tolerated and cost-efficient treatment options. However, the molecular pathways of their effects are not fully elucidated yet. Based on previous literature, we assume that probiotics can positively influence inflammatory mechanisms. We aimed at analyzing the effects of probiotics on gene expression of inflammation genes as part of the randomized, placebo-controlled, multispecies probiotics PROVIT study in Graz, Austria. Fasting blood of 61 inpatients with MDD was collected before and after four weeks of probiotic intake or placebo. We analyzed the effects on gene expression of tumor necrosis factor (TNF), nuclear factor kappa B subunit 1 (NFKB1) and interleukin-6 (IL-6). In IL-6 we found no significant main effects for group (F(1,44) = 1.33, p = ns) nor time (F(1,44) = 0.00, p = ns), but interaction was significant (F(1,44) = 5.67, p < 0.05). The intervention group showed decreasing IL-6 gene expression levels while the placebo group showed increasing gene expression levels of IL-6. Probiotics could be a useful additional treatment in MDD, due to their anti-inflammatory effects. Results of the current study are promising, but further studies are required to investigate the beneficial effects of probiotic interventions in depressed individuals.

Major depressive disorder is associated with changes in a cluster of serum and urine biomarkers

2019 ◽  
Vol 125 ◽  
pp. 109796 ◽  
Author(s):  
Erin M. van Buel ◽  
Marcus J.M. Meddens ◽  
Eduard A. Arnoldussen ◽  
Edwin R. van den Heuvel ◽  
Willem C. Bohlmeijer ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Urine Biomarkers ◽  
Serum And Urine

scholarly journals Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications

2021 ◽  
Author(s):  
Zezhi Li ◽  
Meihua Ruan ◽  
Jun Chen ◽  
Yiru Fang
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Research Progress ◽  
Social Psychological ◽  
Major Depressive ◽  
Neuroscience Research ◽  
Great Progress ◽  
Treatment Measures ◽  
Biological Aspects ◽  
Made In

AbstractMajor depressive disorder (MDD), also referred to as depression, is one of the most common psychiatric disorders with a high economic burden. The etiology of depression is still not clear, but it is generally believed that MDD is a multifactorial disease caused by the interaction of social, psychological, and biological aspects. Therefore, there is no exact pathological theory that can independently explain its pathogenesis, involving genetics, neurobiology, and neuroimaging. At present, there are many treatment measures for patients with depression, including drug therapy, psychotherapy, and neuromodulation technology. In recent years, great progress has been made in the development of new antidepressants, some of which have been applied in the clinic. This article mainly reviews the research progress, pathogenesis, and treatment of MDD.

scholarly journals Urine proteome changes in a chronic unpredictable mild stress (CUMS) mouse model of major depressive disorder

2020 ◽  
Author(s):  
Yuhang Huan ◽  
Jing Wei ◽  
Tong Su ◽  
Youhe Gao
Keyword(s):  
Major Depressive Disorder ◽  
Mouse Model ◽  
Depressive Disorder ◽  
Mild Stress ◽  
Chronic Unpredictable Mild Stress ◽  
Major Depressive ◽  
Urine Proteome ◽  
Random Combination ◽  
Differential Proteins ◽  
Proteome Changes

AbstractBackgroundMajor depressive disorder (MDD) is a prevalent complex psychiatric disorder with a high prevalence rate. Because MDD is a systemic multifactorial disorder involving complex interactions and disturbances of various molecular pathways, there are no effective biomarkers for clinical diagnosis. Urine is not subjected to homeostatic control, allowing it to reflect the sensitive and comprehensive changes that occur in various diseases. In this study, we examined the urine proteome changes in a CUMS mouse model of MDD.MethodsMale C57BL/6 mice were subjected to chronic unpredictable mild stress for 5 weeks. The tail suspension test (TST) and sucrose consumption test (SCT) were then applied to evaluate depression-like behaviors. The urine proteomes on day 0 and day 36 in the CUMS group were profiled by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).ResultsA total of 45 differential proteins were identified, 24 of which have been associated with the pathogenic mechanisms of MDD, while 10 proteins have been previously suggested as MDD biomarkers. There was an average of two differential proteins that were identified through 1048574 random combination statistical analyses, indicating that at least 95% of the differential proteins were reliable and not the result of random combination. The differential proteins were mainly associated with blood coagulation, inflammatory responses and central nervous system development.ConclusionsOur preliminary results indicated that the urine proteome can reflect changes associated with MDD in the CUMS model, which provides potential clues for the diagnosis of clinical MDD patients.

Sign in / Sign up

Export Citation Format

Share Document